Cardiac contractility modulation is a therapy for patients with moderate to severe heart failure who remain symptomatic despite optimal medical therapy and who could benefit from improved cardiac output. It works by using a pacemaker-like device that applies non-excitatory electrical signals timed to the electrical action of the cardiac cycle, enhancing the strength of ventricular contraction without directly affecting cardiac rhythm or increasing the heart's oxygen demand. The therapy, delivered through the OPTIMIZER Smart System device, received United States Food and Drug Administration approval on March 21, 2019, based on the FIX-HF-5C trial.
Facts
FAQs
Which heart failure patients is cardiac contractility modulation approved for in the United States?
Approved for New York Heart Association class III heart failure with an ejection fraction of 25 to 45 percent, in normal sinus rhythm and not indicated for cardiac resynchronization therapy.
The United States Food and Drug Administration approved the OPTIMIZER Smart System, the device that delivers cardiac contractility modulation, on March 21, 2019. The approval is narrower than the general idea of a therapy for heart failure. The device is indicated to improve six-minute hall walk distance, quality of life and functional status in patients with New York Heart Association class III heart failure who remain symptomatic despite guideline directed medical therapy, who are in normal sinus rhythm, who are not indicated for cardiac resynchronization therapy, and who have a left ventricular ejection fraction ranging from 25 percent to 45 percent. This describes a regulatory indication and is not medical advice. A cardiologist decides who qualifies.
Connections
Treats
Source Cardiac contractility modulation (Wikipedia)
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundation
2. Cardiac contractility modulation (Wikipedia)
https://en.wikipedia.org/wiki/Cardiac_contractility_modulation, lead section
Cardiac contractility modulation is a therapy which is intended for the treatment of patients with moderate to severe heart failure (NYHA class II-IV) with symptoms despite optimal medical therapy who can benefit from an improvement in cardiac output.
Section: History (origin-year)
An implantable cardiac contractility modulation device was received by a patient for the first time in 2001.
Treats: Heart Failure, Lead: treats Heart Failure
Cardiac contractility modulation is a therapy which is intended for the treatment of patients with moderate to severe heart failure (NYHA class II-IV) with symptoms despite optimal medical therapy who can benefit from an improvement in cardiac output.
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.
View At A Past Year
Choose a year to see this entry's facts and connections as the atlas records them at that moment: what it held then, what it held instead, and what it had not yet adopted. Choose Present for the current record.